Cargando…

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans

BACKGROUND: In Alzheimer’s disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hölttä, Mikko, Dean, Robert A., Siemers, Eric, Mawuenyega, Kwasi G., Sigurdson, Wendy, May, Patrick C., Holtzman, David M., Portelius, Erik, Zetterberg, Henrik, Bateman, Randall J., Blennow, Kaj, Gobom, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780148/ https://www.ncbi.nlm.nih.gov/pubmed/26948580 http://dx.doi.org/10.1186/s13195-016-0178-x

Ejemplares similares

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation
por: Hajós, Mihály, et al.
Publicado: (2013)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015)

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
por: Portelius, Erik, et al.
Publicado: (2010)

γ‐Secretase modulators show selectivity for γ‐secretase–mediated amyloid precursor protein intramembrane processing
por: Weber, Tobias A., et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer’s disease subjects
por: Hata, Saori, et al.
Publicado: (2012)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Inhibition of γ-Secretase Leads to an Increase in Presenilin-1
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2017)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
por: Weiner, Sophia, et al.
Publicado: (2022)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus
por: Weiner, Sophia, et al.
Publicado: (2023)

Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
por: Minta, Karolina, et al.
Publicado: (2020)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023)

γ-Secretase Components as Predictors of Breast Cancer Outcome
por: Peltonen, Hanna M., et al.
Publicado: (2013)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site
por: Uemura, Kengo, et al.
Publicado: (2010)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Presenilin/γ-Secretase and Inflammation
por: Saura, Carlos A.
Publicado: (2010)

γ-Secretase in Alzheimer’s disease
por: Hur, Ji-Yeun
Publicado: (2022)

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
por: Tosun, Duygu, et al.
Publicado: (2021)

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification
por: Hampel, Harald, et al.
Publicado: (2020)

Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases
por: Minta, K., et al.
Publicado: (2020)

Ex vivo(18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
por: Portelius, Erik, et al.
Publicado: (2017)

γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
por: Lessard, Christian B., et al.
Publicado: (2020)

Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus
por: Jeppsson, A., et al.
Publicado: (2016)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Structure-function relationship of γ-secretase
por: Tomita, Taisuke
Publicado: (2012)

The dynamic conformational landscape of γ-secretase
por: Elad, Nadav, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ponh7ltsqa6h7cen3qrmnh27v8